Traditional Medicare has been an important proving ground for U.S. healthcare for decades, and Medicare reimbursement has been used to support rural healthcare and medical education. In an opinion piece published by JAMA, Gretchen Jacobson and David Blumenthal of The Commonwealth Fund discuss some of the pitfalls of shrinking enrollment in traditional Medicare as the proportion of beneficiaries in Medicare Advantage plans grows.
About 46% of people eligible for Medicare are enrolled in Medicare Advantage (MA) plan and in the next few years the balance is likely to tip so that more than half of beneficiaries will be in MA plans.
MA has grown for several reasons, some of which can be traced back to the generous payments to the plans and the extras they can offer beneficiaries. The plans say they bring efficiency and coordination to beneficiaries’ health care.
Regardless of the reasons, the shift to MA plans has serious implications for Medicare and overall U.S. healthcare system, Gretchen Jacobson, Ph.D., and David Blumenthal, M.D., M.P.P., argue in an opinion piece published online by JAMA this week.
Here are four of the points they make:
Developments in healthcare often take policy makers by surprise, observe Jacobson and Blumenthal. But the migration of an increasing proportion of Medicare beneficiaries into MA plans is a long-term trend.
“While meeting the challenge created by the decline in enrollment in traditional Medicare will raise important issues about roles of regulation and competition in Medicare Advantage,” wrote Jacobson and Blumenthal, “it would be better to confront and resolve those issues now, before traditional Medicare can no longer function to effectively inform the management of the healthcare system.”
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
FDA Clears Phase 2 Trial of Cannabis in PTSD
November 20th 2024After a three-year negotiation, the FDA has dropped its objection to allowing patients to self-titrate dosing of smoked cannabis. But regulators want to see additional information about the device that will be used for inhalation.
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen